This is what companies around the world are attempting to do as they dive deeper into the genomics industry to find the key behind chronic inflammation. It has often been referred to as a silent killer and is a starting point for many different diseases and illnesses. Investors looking to hit a homerun with a speculative biotech or pharmaceutical company will want to consider some of the following stocks.
In this industry, the companies with the deepest pockets have the longest runway for success. Companies like Pfizer (NYSE:PFE), Johnson & Johnson (NYSE:JNJ), and AbbVie (NYSE:ABBV) are all heavily inverted and involved in finding a treatment for inflammation.
Perhaps more interesting is the recently changed company Ludwig Enterprises (OTC:LUDG). Ludwig is forging partnerships like one with Emerson Urology Associates where its upcoming Ludwig mRNA Inflammatory Index will be used when it is ready. It is also using the data from this index to create early indications and triggers for early detection of diseases like cancer, strokes, and heart disease. These advancements from Ludwig are tremendous and could lead to a future where life expectancy is lengthened and difficult and traumatic battles against diseases are reduced significantly.
Featured: $LUDG $PFE $JNJ $ABBV
